Last updated on July 2011

TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas


Brief description of study

The primary objective is to determine the local and systemic anti-tumor effects of intratumoral injection of VTX-2337, a TLR8 agonist, in combination with low-dose local radiation at a single tumor site, in patients with recurrent b-cell lymphoma.

Clinical Study Identifier: NCT01396018

Contact Investigators or Research Sites near you

Start Over

Ronald Levy

Stanford University School of Medicine
Stanford, CA United States
  Connect »